Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Stock Fails to Meet Nasdaq Minimum Bid Requirement

Premium

Arrowhead Research, the parent firm of Calando Pharmaceuticals, said last week that it has received notice from the Nasdaq Stock Market that it does not comply with the exchange's $1 minimum bid requirement for continued listing.

The company said it has been given 180 days, until March 15, 2010, to regain compliance by maintaining a minimum closing bid price of $1 per share for 10 consecutive business days. If it does not regain compliance, Arrowhead's stock will be subjected to delisting, the company said.

Arrowhead has been struggling as of late with a deflated stock price and dwindling cash reserves. In August, the company said that it had shut down Calando's laboratory to trim costs, but that it was optimistic that it would be able to partner the subsidiary's RNAi drug-delivery technology (see RNAi News, 8/13/2009).

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.